Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

Part of paid clinical trials in Kansas City, Kansas.

Sponsor
University of Kansas Medical Center
Study ID
NCT00759642
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • lapatinib — DRUG
    lapatinib 1500 mg PO daily

Study Details

Hormone receptor positive breast cancer is the most common type of breast cancer, comprising 70-80% of all breast cancers. Endocrine therapy is the main type of initial treatment for patients with your type of breast cancer. Endocrine therapy is treatment that tries to remove, or block certain hormones from binding to the cancer cells and thus slow or stop the growth of cancer. Although most patients with your type of breast cancer respond initially to endocrine therapies, it can lose its effectiveness. New therapies for this type of cancer are needed.

Key Dates

Start date
Mar 31, 2009
Status verified
Jun 2019
Primary completion
Nov 30, 2015
Completion
Aug 20, 2018

Study Design

Enrollment
33 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Lapatinib
    lapatinib

Primary Outcome Measure

Progression Free Survival [ Time Frame: 12 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
University of Kansas Medical CenterKansas CityKansas66160-
Cotton-O-Neil Cancer Center (Stormont Vail Health Care)TopekaKansas66606-
Truman Medical CenterKansas CityMissouri64108-

Find similar trials in Kansas City, KS

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
University of Kansas Medical Center· Kansas City, KSCotton-O-Neil Cancer Center (Stormont Vail Health Care)· Topeka, KSTruman Medical Center· Kansas City, MO

Related Studies